CAP_320_BB_Investor _and_Financial_Relations_Cases_f10

CAP_320_BB_Investor _and_Financial_Relations_Cases_f10 -...

Info iconThis preview shows pages 1–2. Sign up to view the full content.

View Full Document Right Arrow Icon

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
This is the end of the preview. Sign up to access the rest of the document.

Unformatted text preview: Investor Relations IR-1 Problem Genetech, Inc. Genetech, Inc. is a small biomedical research firm located in Southern California. Specializing in genetic engineering, the firm has participated heavily in the Human Genome project and has built a reputation for pioneering work in the field. For example, scientists in the company have successfully isolated the genetic pointers for Parkinsons Disease. Stock values have increased steadily over the years, with sharp upswings every time the public has heard about some new breakthrough in the field. Now, however, Genetech faces a serious threat. Public sentiment towards genetic engineering has turned skeptical, and firms in the field have been forced to face serious questions about the safety, ethics and efficacy of their work. One local anti-stem cell research zealot has claimed Genetech is working with abortion clinics to obtain fetuses for company research. Even though groundless, the claim has planted more seeds of doubt in potential investors. Some politicians have even threatened legislation to outlaw more seeds of doubt in potential investors....
View Full Document

This note was uploaded on 05/16/2011 for the course CAP 321 taught by Professor Professorwalz during the Spring '11 term at Grand Valley State University.

Page1 / 2

CAP_320_BB_Investor _and_Financial_Relations_Cases_f10 -...

This preview shows document pages 1 - 2. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online